Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425241 | 0.91 | CCR4 (0.55) | CCR4PTGDR2 | |
| SCHEMBL2422198 | 0.89 | MEN1 (0.47) | CCR4PTGDR2 | |
| SCHEMBL2422056 | 0.89 | CCR4 (0.61) | CCR4 | |
| SCHEMBL12282384 | 0.87 | CCR4 (0.76) | CCR4PTGDR2 | |
| SCHEMBL2421003 | 0.87 | CCR4 (0.56) | CCR4 | |
| SCHEMBL2419196 | 0.87 | EDNRA (0.46) | CCR4PTGDR2 | |
| SCHEMBL2419910 | 0.86 | MEN1 (0.50) | CCR4PTGDR2 | |
| SCHEMBL2429470 | 0.86 | MEN1 (0.53) | CCR4PTGDR2 | |
| SCHEMBL2422888 | 0.86 | CCR4 (0.61) | CCR4 | |
| SCHEMBL2421587 | 0.85 | CCR4 (0.57) | CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374802-B1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA HAKKO KIRIN CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8673908-B2 | Kynurenine production inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2374802-A1 | KYNURENINE PRODUCTION INHIBITOR | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYOWA KIRIN CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237584-A1 | KYNURENINE PRODUCTION INHIBITOR | KYNU, KMO, IDO1 | CCR4 3284/4885PTGDR2 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.